Schaper Benz & Wise Investment Counsel Inc. WI Has $25.58 Million Holdings in Stryker Co. (NYSE:SYK)

Schaper Benz & Wise Investment Counsel Inc. WI lowered its position in Stryker Co. (NYSE:SYK) by 0.2% in the 3rd quarter, Holdings Channel reports. The firm owned 118,240 shares of the medical technology company’s stock after selling 198 shares during the quarter. Stryker accounts for approximately 3.2% of Schaper Benz & Wise Investment Counsel Inc. WI’s portfolio, making the stock its 2nd biggest position. Schaper Benz & Wise Investment Counsel Inc. WI’s holdings in Stryker were worth $25,575,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Buckingham Capital Management Inc. raised its stake in shares of Stryker by 12.3% during the first quarter. Buckingham Capital Management Inc. now owns 34,399 shares of the medical technology company’s stock valued at $6,794,000 after acquiring an additional 3,769 shares in the last quarter. Bath Savings Trust Co raised its stake in shares of Stryker by 5.5% during the second quarter. Bath Savings Trust Co now owns 75,254 shares of the medical technology company’s stock valued at $15,470,000 after acquiring an additional 3,946 shares in the last quarter. First Financial Bank Trust Division raised its stake in shares of Stryker by 1.0% during the second quarter. First Financial Bank Trust Division now owns 48,935 shares of the medical technology company’s stock valued at $10,060,000 after acquiring an additional 496 shares in the last quarter. Private Trust Co. NA raised its stake in shares of Stryker by 15.8% during the second quarter. Private Trust Co. NA now owns 21,250 shares of the medical technology company’s stock valued at $4,368,000 after acquiring an additional 2,905 shares in the last quarter. Finally, LVM Capital Management Ltd. MI raised its stake in shares of Stryker by 0.6% during the second quarter. LVM Capital Management Ltd. MI now owns 26,608 shares of the medical technology company’s stock valued at $5,470,000 after acquiring an additional 167 shares in the last quarter. 73.13% of the stock is owned by institutional investors and hedge funds.

NYSE SYK traded down $1.00 on Friday, hitting $199.78. The stock had a trading volume of 1,420,532 shares, compared to its average volume of 1,230,180. The business’s fifty day moving average price is $213.55 and its 200 day moving average price is $205.53. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.18 and a quick ratio of 1.35. Stryker Co. has a 52-week low of $144.75 and a 52-week high of $223.45. The stock has a market cap of $74.21 billion, a price-to-earnings ratio of 27.33, a price-to-earnings-growth ratio of 2.43 and a beta of 0.80.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $1.91 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.90 by $0.01. Stryker had a net margin of 23.55% and a return on equity of 25.33%. The business had revenue of $3.59 billion for the quarter, compared to analyst estimates of $3.58 billion. During the same period in the previous year, the company earned $1.69 earnings per share. The business’s revenue for the quarter was up 10.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Stryker Co. will post 8.23 EPS for the current year.

In other Stryker news, Director Srikant M. Datar sold 350 shares of Stryker stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $215.00, for a total value of $75,250.00. Following the transaction, the director now directly owns 6,844 shares of the company’s stock, valued at $1,471,460. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kevin Lobo sold 19,286 shares of Stryker stock in a transaction on Thursday, October 31st. The stock was sold at an average price of $215.71, for a total transaction of $4,160,183.06. The disclosure for this sale can be found here. Insiders sold 67,524 shares of company stock worth $14,731,927 over the last ninety days. Corporate insiders own 7.20% of the company’s stock.

A number of brokerages recently commented on SYK. Raymond James set a $240.00 price objective on shares of Stryker and gave the stock a “buy” rating in a research note on Friday, July 26th. Royal Bank of Canada set a $220.00 price objective on shares of Stryker and gave the stock a “buy” rating in a research note on Friday, July 26th. UBS Group boosted their price objective on shares of Stryker from $220.00 to $225.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Stifel Nicolaus boosted their price objective on shares of Stryker from $230.00 to $245.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Finally, Barclays downgraded shares of Stryker from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $226.00 to $207.00 in a research note on Tuesday. Seven research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company’s stock. Stryker presently has an average rating of “Buy” and an average price target of $219.08.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Read More: Most Volatile Stocks

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.